靶向α核素治疗药物临床前评价中内照射剂量估算的研究进展  

Research progress on estimating internal radiation dose of radiopharmaceuticals for targetedαradionuclide therapy in preclinical evaluation

作　　者：陈绪福 高洁 王钊龙 卢海丽 张舒 韩宗泰 李建国[1,2] Chen Xufu;Gao Jie;Wang Zhaolong;Lu Haili;Zhang Shu;Han Zongtai;Li Jianguo(Division of Radiation Medicine and Environmental Medicine,China Institute for Radiation Protection,CAEA Center of Excellence on Nuclear Technology Applications for Nonclinical Evaluation for Radiopharmaceutical,CNNC Key Laboratory on Radio-Toxicology and Radiopharmaceutical Preclinical Evaluation,Shanxi Key Laboratory of Drug Toxicology and Preclinical Studies for Radiopharmaceutical,Taiyuan 030006,China;Institute of Medical Aspects of Specific Environments,Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]中国辐射防护研究院放射医学与环境医学研究所、国家原子能机构(CAEA)核技术(放射性药物非临床评价)研发中心、中核放射毒理与放射性药物临床前评价重点实验室、药物毒理及放射性药物临床前研究山西省重点实验室,太原030006 [2]山西医科大学特种医学研究院,太原030001

出　　处：《中华核医学与分子影像杂志》2025年第1期57-60,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：中央引导地方科技发展资金项目(YDZJSX2021B018);同位素及药物国家工程研究中心同位素及药物创新基金项目(TWSCX-2023-CXJJ-10-1)。

摘　　要：靶向α核素治疗药物因具有放射性、辐射损伤风险等特殊性,在临床前评价中进行内照射剂量估算对正确评价药物的疗效和安全性以及后续的临床研究十分必要。该文针对基于临床前数据进行靶向α核素治疗药物的内照射剂量估算的研究现状进行了阐述,以期增进人们对内照射剂量估算的理解,并为放射性治疗药物的临床前评价提供参考。Due to the specificity of radiopharmaceuticals for targetedαradionuclide therapy,such as radioactivity and radiation damage risk,it is necessary to estimate the internal radiation dose in preclinical evaluation to correctly evaluate the efficacy and safety of the drug,as well as in subsequent clinical studies.This review illustrates current research status of estimating internal radiation dose of targetedαradionuclide therapeutic radiopharmaceuticals based on preclinical studies,in order to add insights for understanding estimation of radiopharmaceuticals internal radiation dose and provide reference for the preclinical evaluation of radiopharmaceuticals.

关 键 词：放射疗法 Α粒子 辐射剂量 发展趋势 

分 类 号：R144.1[医药卫生—公共卫生与预防医学]